EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity-Reference-Cited by-同舟云学术

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity

Published:2021-02-15 Issue:5 Volume:35 Page:1521-1526
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Berg Johannes Lorenz,Perfler Bianca,Hatzl Stefan^ORCID,Uhl Barbara,Reinisch Andreas,Pregartner Gudrun,Berghold Andrea,Penz Thomas,Schuster Michael^ORCID,Geissler Klaus^ORCID,Prokesch Andreas,Müller-Tidow Carsten^ORCID,Hoefler Gerald^ORCID,Kashofer Karl^ORCID,Wölfler Albert,Sill Heinz^ORCID,Caraffini Veronica^ORCID,Zebisch Armin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-021-01161-0.pdf

Reference15 articles.

1. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e393.

2. Wandler A, Shannon K Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Cold Spring Harb Perspect Med. 2018; 8: https://doi.org/10.1101/cshperspect.a031526.

3. Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, et al. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia. 2016;30:1335–43.

4. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J. Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem. 2007;14:601–23.

5. Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013;33:313–8.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer;Biomedicine & Pharmacotherapy;2024-06

2. Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy;Molecules;2021-12-14

3. The Mutational Landscape of Myeloid Leukaemia in Down Syndrome;Cancers;2021-08-18

4. Next generation epigenetic modulators to target myeloid neoplasms;Current Opinion in Hematology;2021-07-15